Friday, June 28, 2013 2:24:12 PM
LONDON, Fri Jun 28, 2013 7:58am EDT
(Reuters) -
Experts at the European Medicines Agency have recommended approval of Bayer's drug Stivarga for the treatment of metastatic colorectal cancer.
Friday's positive decision from EMA's Committee for Medicinal Products for Human Use (CHMP) follows an earlier green light for the product in the United States.
Stivarga is a pill that works by blocking several enzymes that promote cancer growth.
Under an agreement signed in 2011, Onyx Pharmaceuticals will receive a 20 percent royalty payment on global sales of Stivarga.
Bayer and Onyx jointly market Stivarga in the United States, while Bayer has sole marketing rights in the rest of the world.
______________________________________________________________
http://www.reuters.com/article/2013/06/28/bayer-europe-cancer-idUSL5N0F03AA20130628
ONXX
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM